tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment
PremiumCompany AnnouncementsTempest Therapeutics’ Promising Advances in Liver Cancer Treatment
4M ago
Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial
Premium
The Fly
Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial
4M ago
Tempest Therapeutics Secures $4.1M in Direct Offering
Premium
Company Announcements
Tempest Therapeutics Secures $4.1M in Direct Offering
4M ago
Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
PremiumRatingsTempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
5M ago
Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)
Premium
The Fly
Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)
5M ago
Cautious Optimism for Tempest Therapeutics Amid Strategic Reorganization and Promising Amezalpat Data
Premium
Ratings
Cautious Optimism for Tempest Therapeutics Amid Strategic Reorganization and Promising Amezalpat Data
6M ago
Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
PremiumThe FlyTempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
6M ago
Tempest Therapeutics Terminates Loan Agreement with Oxford
Premium
Company Announcements
Tempest Therapeutics Terminates Loan Agreement with Oxford
6M ago
Tempest Therapeutics to explore strategic alternatives
Premium
The Fly
Tempest Therapeutics to explore strategic alternatives
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100